布地奈德雾化吸入联合孟鲁司特钠对支气管哮喘患儿肺功能及CysLTs、FLAPmRNA表达的影响-现代医学

布地奈德雾化吸入联合孟鲁司特钠对支气管哮喘患儿肺功能及CysLTs、FLAPmRNA表达的影响

单位：1. 广元市妇幼保健院儿科, 四川广元 628017;
2. 广元市妇幼保健院妇产科, 四川广元 628017

关键词：布地奈德孟鲁司特钠支气管哮喘肺功能 CysLTs FLAPmRNA 影响

分类号：R725.6

出版年·卷·期（页码）：2017·36·第八期（1127-1130）

摘要：

目的：探讨布地奈德雾化吸入联合孟鲁司特钠对支气管哮喘患儿肺功能及半胱氨酰白三烯（CysLTs）、5-脂氧合酶激活蛋白（FLAP） mRNA表达的影响。方法：选取我院2015年8月~2016年8月收治的支气管哮喘患儿共120例，按照随机原则将患儿分为对照组与研究组，各60例；所有患儿都给予祛痰以及激素等哮喘常规治疗；对照组加上布地奈德混悬液雾化吸入，0.5 mg/次，2次/d；研究组在对照组的基础上口服孟鲁司特钠，4 mg/次，1次/d，睡前服用；2周1疗程；两组患儿均治疗2疗程；比较两组患儿治疗前后6分钟步行距离（6MWD）和肺功能等指标的变化；比较两组患儿治疗前后CysLTs及FLAP mRNA表达的变化。结果：研究组总有效率显著高于对照组（P<0.05）；治疗后研究组患儿6MWD长于对照组（P<0.05），肺功能有明显改善（P<0.05），FVC、FEV1高于对照组，PEER较对照组快；治疗结束后，研究组CysLTs水平及FLAP mRNA的表达量较对照组低（P<0.05）。结论：布地奈德联合孟鲁司特钠能有效改善小儿哮喘患者的肺功能，降低CysLTs水平和FLAP mRNA的表达量，临床疗效确切，不良反应少，有推广和应用价值。

Objective: To investigate the effect of aerosol inhalation of budesonide combined with Singulair on bronchial asthma, pulmonary function and CysLTs FLAPmRNA expression.Methods: A total of 120 children with bronchial asthma in our hospital from August 2015 to August 2016 were randomly divided into control group and study group, 60 cases in each group. Two children before entering the group were treated with oxygen, expectorant, anti infection, glucocorticoid and other conventional treatment; the control group was given budesonide suspension liquid atomization inhalation, 0.5 mg per time, twice per day, on top of this, the research group took orally Singulair, 4 mg/, 1/d, 2 week course at bedtime. The two groups were treated for 2 courses before and after treatment, and comparison was made between the two groups; 6 minutes walking distance(6MWD) and pulmonary function(FVC, PEER, FEV1) and other indicators, as well as the changes of the expression of CysLTs and FLAP mRNA before and after treatment in the two groups were compared. Results: The total effective rate was significantly higher than that of control group(P<0.05); after treatment in the study group, 6MWD was longer than that in the control group(P<0.05), lung function was significantly improved(P<0.05), FVC and FEV1were higher, PEER was faster; After treatment, the serum levels of CysLTs and FLAP in the study group were lower than those in the control group(P<0.05)(mRNA).Conclusion: The curative effect of budesonide combined with Singulair in the treatment of infantile asthma is effective, which effectively improves pulmonary function in children, reduces the level of serum CysLTs and expression of FLAP mRNA, and has less adverse reactions, it is worthy of clinical application.

参考文献：

[1] 宋芬乐,成焕吉,李艳春,等. 支气管哮喘儿童哮喘控制与治疗现状的临床观察[J].中国妇幼保健, 2016,31(9):1891-1893.
[2] VIJAYAKUMAR J, SUBRAMANIAN S, SINGH P, et al. Arterial inflammation in bronchial asthma[J].J Nucl Cardiol,2013,20(3):385-395.
[3] 洪建国. 中国儿童支气管哮喘防治指南修订要点的探讨[J].临床儿科杂志,2014,32(2):101-103.
[4] PETERS S P, BLEECKER E R, CANONICA G W, et al. Serious asthma events with budesonide plus formoterol vs. budesonide alone[J].New Engl J Med,2016,375(9):850-860.
[5] MILIGKOS M, BANNURU R R, ALKOFIDE H, et al. Leukotriene-receptor antagonists versus placebo in the treatment of asthma in adults and adolescents:a systematic review and meta-analysis[J].Ann Intern Med,2015,163(10):756-767.
[6] OTUNCTEMUR A, OZBEK E, CEKMEN M, et al. Protective effect of montelukast which is cysteinyl-leukotriene receptor antagonist on gentamicin-induced nephrotoxicity and oxidative damage in rat kidney[J].Renal failure,2013, 35(3):403-410.
[7] 黄磊瑛,金雅,徐小桥. 哮喘患儿外周血半胱氨酰白三烯水平及5-脂氧合酶激活蛋白mRNA基因表达水平及其临床意义[J].广西医学,2015,37(8):1121-1124.
[8] 全国儿科哮喘协作组. 儿童哮喘诊断标准[J].浙江中西医结合杂志, 2003,13(1):27-27.
[9] 马旭升,涂林修,梅依君,等. 儿童哮喘规范化管理治疗效果评价[J].临床儿科杂志, 2015,33(8):706.
[10] 刘传合, 陈育智. 儿童哮喘流行病学及防治现状分析[J].中国实用儿科杂志,2013,28(11):809-811.
[11] OLIVER B G G, ROBINSON P, PETERS M, et al. Viral infections and asthma:an inflammatory interface?[J].Eur Respir J, 2014,44(6):1666-1681.
[12] STARLING A L B, GONCALVES D U, PERUHYPE M V, et al. Cytokines, chemokines and leukotrienes profile and signature analysis in HTLV-1 infection as an evidence of disease progression[J].Retrovirology, 2014,11(1):1-1.
[13] YADAV U C S, SRIVASTAVA S K. Cysteinyl leukotrienes(CysLTs):Role in obesity-induced asthma[J].Curr Mol Med,2015,15(7):598-605.
[14] BOYCE J A, BARRETT N A. Cysteinyl leukotrienes:an innate system for epithelial control of airway smooth muscle proliferation?[J].Am J Resp Crit Care,2015,191(5):496-497.
[15] RUDIGER J J, GENCAY M, YANG J Q, et al. Fast beneficial systemic anti-inflammatory effects of inhaled budesonide and formoterol on circulating lymphocytes in asthma[J].Respirology,2013,18(5):840-847.
[16] MATSUSE H, KOHNO S. Leukotriene receptor antagonists pranlukast and montelukast for treating asthma[J].Expert Opin Pharmaco,2014,15(3):353-363.
[17] LIAO S S. Efficacy of Montelukast combined budesonide inhalation therapy on children with cough variant asthma[J].China Med EN, 2013,20(9):126-126.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录